MACOM Technology Solutions Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MACOM Technology Solutions Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $967.26M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $729.58M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $648.41M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $675.17M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $606.92M | Nov 13, 2023 |
| FY2020 | Oct 2, 2020 | $147.25M | Nov 18, 2020 |
| FY2020 | Jul 3, 2020 | $137.27M | Nov 18, 2020 |
| FY2020 | Apr 3, 2020 | $126.42M | Nov 18, 2020 |
| FY2020 | Jan 3, 2020 | $119.10M | Nov 18, 2020 |
| FY2020 | Sep 27, 2019 | $112.25M | Nov 18, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 28, 2018 | $151.19M | Nov 16, 2018 |
| FY2018 | Jun 29, 2018 | $137.87M | Nov 16, 2018 |
| FY2018 | Mar 30, 2018 | $150.41M | Nov 16, 2018 |
| FY2018 | Dec 29, 2017 | $130.93M | Nov 16, 2018 |
| FY2018 | Sep 29, 2017 | $166.38M | Nov 16, 2018 |
| FY2018 | Jun 30, 2017 | $194.56M | Nov 16, 2018 |
| FY2018 | Mar 31, 2017 | $186.08M | Nov 16, 2018 |
| FY2018 | Dec 30, 2016 | $151.75M | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | $152.70M | Nov 15, 2017 |
| FY2017 | Jul 1, 2016 | $142.29M | Nov 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $529.00M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $393.77M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $385.80M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $406.18M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $341.86M | Nov 13, 2023 |
| FY2020 | Oct 2, 2020 | $77.72M | Nov 18, 2020 |
| FY2020 | Jul 3, 2020 | $70.88M | Nov 18, 2020 |
| FY2020 | Apr 3, 2020 | $63.37M | Nov 18, 2020 |
| FY2020 | Jan 3, 2020 | $58.20M | Nov 18, 2020 |
| FY2020 | Sep 27, 2019 | $52.93M | Nov 18, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | ($54.21M) | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $76.86M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $91.58M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $439.96M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $37.97M | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | ($46.08M) | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | ($383.80M) | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | ($139.98M) | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | ($169.49M) | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $1.43M | Nov 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $129.65M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $73.67M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $107.40M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $132.67M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $81.00M | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | $3.39M | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | ($380.38M) | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | ($106.52M) | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | ($16.08M) | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $13.25M | Nov 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $244.47M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $182.16M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $148.55M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $148.23M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $138.84M | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | $141.33M | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | $163.47M | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | $177.71M | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | $147.99M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $107.70M | Nov 16, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $154.88M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $137.95M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $129.85M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $125.28M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $122.01M | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | $124.31M | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | $153.29M | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | $161.67M | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | $187.89M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $145.43M | Nov 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $235.37M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $162.64M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $166.92M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $176.98M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $148.41M | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | $171.40M | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | $20.70M | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | $36.29M | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | $61.05M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $79.23M | Nov 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $42.55M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $22.44M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $24.70M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $26.51M | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | $17.95M | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | $17.57M | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | $37.96M | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | $53.04M | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | $32.80M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $31.33M | Nov 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $2.10B | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $1.76B | Nov 14, 2025 |
| FY2024 | Sep 29, 2023 | $1.55B | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $1.57B | Nov 13, 2023 |
| FY2022 | Oct 1, 2021 | $1.13B | Nov 14, 2022 |
| FY2021 | Oct 2, 2020 | $1.15B | Nov 15, 2021 |
| FY2020 | Sep 27, 2019 | $1.11B | Nov 18, 2020 |
| FY2019 | Sep 28, 2018 | $1.48B | Nov 26, 2019 |
| FY2018 | Sep 29, 2017 | $1.64B | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | $1.19B | Nov 15, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $776.27M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $629.30M | Nov 14, 2025 |
| FY2024 | Sep 29, 2023 | $605.64M | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $729.07M | Nov 13, 2023 |
| FY2022 | Oct 1, 2021 | $662.41M | Nov 14, 2022 |
| FY2021 | Oct 2, 2020 | $846.28M | Nov 15, 2021 |
| FY2020 | Sep 27, 2019 | $791.68M | Nov 18, 2020 |
| FY2019 | Sep 28, 2018 | $813.82M | Nov 26, 2019 |
| FY2018 | Sep 29, 2017 | $859.75M | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | $725.77M | Nov 15, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $1.33B | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $1.13B | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $947.60M | Nov 14, 2025 |
| FY2025 | Sep 30, 2022 | $842.75M | Nov 14, 2025 |
| FY2024 | Oct 1, 2021 | $471.74M | Nov 12, 2024 |
| FY2023 | Oct 2, 2020 | $300.15M | Nov 13, 2023 |
| FY2022 | Sep 27, 2019 | $313.90M | Nov 14, 2022 |
| FY2021 | Sep 28, 2018 | $668.68M | Nov 15, 2021 |
| FY2020 | Sep 29, 2017 | $777.37M | Nov 18, 2020 |
| FY2019 | Sep 30, 2016 | $462.78M | Nov 26, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $336.32M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $332.20M | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | $323.40M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $311.42M | Nov 12, 2024 |
| FY2022 | Oct 1, 2021 | $314.24M | Nov 14, 2022 |
| FY2021 | Oct 2, 2020 | $315.01M | Nov 15, 2021 |
| FY2020 | Sep 27, 2019 | $314.73M | Nov 18, 2020 |
| FY2019 | Sep 28, 2018 | $314.08M | Nov 26, 2019 |
| FY2018 | Sep 29, 2017 | $313.77M | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | $120.02M | Nov 15, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | ($240.06M) | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | ($185.85M) | Nov 14, 2025 |
| FY2024 | Sep 29, 2023 | ($262.71M) | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | ($354.29M) | Nov 13, 2023 |
| FY2022 | Oct 1, 2021 | ($801.75M) | Nov 14, 2022 |
| FY2021 | Oct 2, 2020 | ($839.73M) | Nov 15, 2021 |
| FY2020 | Sep 27, 2019 | ($791.77M) | Nov 18, 2020 |
| FY2019 | Sep 28, 2018 | ($407.98M) | Nov 26, 2019 |
| FY2018 | Sep 29, 2017 | ($266.98M) | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | ($97.49M) | Nov 15, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | $112.14M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | $146.81M | Nov 14, 2025 |
| FY2024 | Sep 29, 2023 | $173.95M | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $119.95M | Nov 13, 2023 |
| FY2022 | Oct 1, 2021 | $156.54M | Nov 14, 2022 |
| FY2021 | Oct 2, 2020 | $129.44M | Nov 15, 2021 |
| FY2020 | Sep 27, 2019 | $75.52M | Nov 18, 2020 |
| FY2019 | Sep 28, 2018 | $94.68M | Nov 26, 2019 |
| FY2019 | Sep 29, 2017 | $130.10M | Nov 26, 2019 |
| FY2019 | Sep 30, 2016 | $332.98M | Nov 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | 0 | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | 1 | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | 1 | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | 6 | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | 0 | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | 0 | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | (5) | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | (2) | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | (2) | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | 0 | Nov 16, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | 0 | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | 1 | Nov 14, 2025 |
| FY2025 | Sep 29, 2023 | 1 | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | 6 | Nov 12, 2024 |
| FY2023 | Oct 1, 2021 | 0 | Nov 13, 2023 |
| FY2022 | Oct 2, 2020 | 0 | Nov 14, 2022 |
| FY2021 | Sep 27, 2019 | (5) | Nov 15, 2021 |
| FY2020 | Sep 28, 2018 | (2) | Nov 18, 2020 |
| FY2019 | Sep 29, 2017 | (2) | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | 0 | Nov 16, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 3, 2025 | 74.48M | Nov 14, 2025 |
| FY2025 | Sep 27, 2024 | 72.20M | Nov 14, 2025 |
| FY2024 | Sep 29, 2023 | 70.99M | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | 70.00M | Nov 13, 2023 |
| FY2022 | Oct 1, 2021 | 68.85M | Nov 14, 2022 |
| FY2021 | Oct 2, 2020 | 66.90M | Nov 15, 2021 |
| FY2020 | Sep 27, 2019 | 66.15M | Nov 18, 2020 |
| FY2019 | Sep 28, 2018 | 65.18M | Nov 26, 2019 |
| FY2018 | Sep 29, 2017 | 64.26M | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | 53.69M | Nov 15, 2017 |